Sparsentan

Sparsentan, sold under the brand name Filspari, is a medication used for the treatment of primary immunoglobulin A nephropathy.[1] Sparsentan is an endothelin and angiotensin II receptor antagonist.[1]

Sparsentan
Clinical data
Trade namesFilspari
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

It was approved for medical use in the United States in February 2023.[1][2]

Medical uses

Sparsentan is indicated to reduce proteinuria in people with primary immunoglobulin A nephropathy.[1]

Society and culture

Sparsentan is approved in the US under accelerated approval based on reduction of proteinuria.[1]

References

  1. "Filspari- sparsentan tablet, film coated". DailyMed. 17 February 2023. Retrieved 6 March 2023.
  2. "Travere Therapeutics Announces FDA Accelerated Approval of Filspari (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy" (Press release). Travere Therapeutics. 17 February 2023. Retrieved 17 February 2023 via GlobeNewswire.
  • Clinical trial number NCT03762850 for "A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.